Ana Custodio
Overview
Explore the profile of Ana Custodio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mitjavila M, Jimenez-Fonseca P, Bello P, Pubul V, Percovich J, Garcia-Burillo A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Mar;
50(8):2486-2500.
PMID: 36877234
Background: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought...
12.
Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, de Castro E, Hernandez R, et al.
J Cancer Res Clin Oncol
. 2022 Aug;
149(7):4077-4089.
PMID: 36042046
Purpose: This study aimed to compare ramucirumab-paclitaxel versus chemotherapy in second-line (2L) advanced gastroesophageal cancer (aGEC) based on HER2 status and analyze prognostic factors. Methods: The study includes patients from...
13.
Zaragoza-Huesca D, Garrido-Rodriguez P, Jimenez-Fonseca P, de Castro E, Sanchez-Canovas M, Visa L, et al.
Biomedicines
. 2022 Jan;
10(1).
PMID: 35052827
Advanced gastric cancer is one of the most thrombogenic neoplasms. However, genetic mechanisms underlying this complication remain obscure, and the molecular and histological heterogeneity of this neoplasm hinder the identification...
14.
Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, et al.
Ther Adv Med Oncol
. 2021 Jul;
13:17588359211019672.
PMID: 34211587
Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the...
15.
Grande E, Rodriguez-Antona C, Lopez C, Alonso-Gordoa T, Benavent M, Capdevila J, et al.
Oncologist
. 2021 Jun;
26(11):941-949.
PMID: 34190375
Background: Sunitinib (SUN)-induced hypoxia within the tumor could promote the activation of the prodrug evofosfamide (EVO), locally releasing the cytotoxic DNA alkylator bromo-isophosphoramide mustard. SUNEVO, a phase II, open-label, single-arm...
16.
Capdevila J, Fazio N, Lopez C, Teule A, Valle J, Tafuto S, et al.
J Clin Oncol
. 2021 May;
39(20):2304-2312.
PMID: 33945297
Purpose: Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression to targeted agents (TAs). We investigated...
17.
Alvarez-Mancenido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano J, et al.
Gastric Cancer
. 2021 Mar;
24(4):926-936.
PMID: 33651195
Background: Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare...
18.
Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castano A, Benavent M, et al.
Neuroendocrinology
. 2021 Jan;
112(1):88-100.
PMID: 33508849
Introduction: Somatostatin analogs (SSA) prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). However, the eligibility criteria in randomized clinical trials (RCTs) have been restricted, which contrasts...
19.
Viudez A, Crespo G, Gomez Dorronsoro M, Arozarena I, Marin-Mendez J, Custodio A, et al.
Pancreatology
. 2020 Dec;
21(1):215-223.
PMID: 33358592
Background: Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated...
20.
Jimenez-Fonseca P, Carmona-Bayonas A, de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, et al.
Gastric Cancer
. 2020 Sep;
24(2):445-456.
PMID: 32970266
Background: The purpose of our study was to develop an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer (AGC), and to...